West Pharmaceutical (WST) PT Raised to $350 at KeyBanc on 'Improving Visibility'

KeyBanc analyst Paul Knight raised the price target on West Pharmaceutical (NYSE: WST) to $350.00 (from $325.00) while maintaining an Overweight rating.

The analyst commented: "Cruising into 2026 and LT Growth Plan with Topto-Bottom Beat and New Capacity Opening; Visibility is building for WST's LT growth construct of 7-9% as seen through ~9% organic growth in 3Q (ex-incentive, ex-CGM) and momentum building from: 1) new capacity in Dublin ramping; and 2) Annex-1 in early days. WST is also executing on key areas such as margin improvement with drug handling and automation in Proprietary Devices. We highlight STVN (Nov. 6) as set up conservatively for 3Q with 5.6% top-line growth est. vs. WST's 5.1% (~9% ex one-offs). We release a revised model to reflect 3Q results, FY25 guidance, FY26 qtrs, and raise our PT to $350 due to improving visibility."

You May Also Be Interested In

• Golar LNG Ltd. (GLNG) PT Raised to $70 at BTIG
• Ascendis Pharma (ASND) PT Raised to $333 at Jefferies
• Legence Corp (LGN) PT Lowered to $100 at BTIG